News

Product Announcements and Company News

ICU Medical has acquired Smiths Medical

For our most recent news and events, please click here >>

To learn more about the acquisition, click here >>

Please direct all media inquiries to Tom McCall, ICU Medical, Corporate Vice President, Global Marketing at tom.mccall@icumed.com.

  1. Sharps Safety Products
    Worldwide Notification Regarding the Recall of Jelco® Hypodermic Needle-Pro® Fixed Needle Insulin Syringe with Skewed Graduation Markings
    Smiths Medical has become aware of specific models and lots of Jelco® Hypodermic Needle-Pro® Fixed Needle Insulin Syringes that may exhibit skewed odd number line graduation markings on their syringe barrels.
  2. Infusion Products
    Smiths Medical and Ivenix Partner to Revolutionize Infusion Management with First-Ever Comprehensive Suite of Infusion Solutions in US Healthcare Market

    Bolstered by strategic investment from Smiths Medical, commercial partnership will offer best-in-class infusion systems designed to improve patient safety, advance clinical efficiency

  3. Respiratory Products
    Introducing the Portex® Acapella® Choice Blue Vibratory Positive Expiratory Pressure (PEP) Therapy System

    Smiths Medical announces the launch of the acapella® choice blue vibratory PEP therapy system. Acapella® is designed to aid in the removal of secretions for patients who have Cystic Fibrosis, Chronic Obstructive Pulmonary Disease (COPD), asthma, lung disease with secretory problems, and patients with atelectasis.

  4. Infusion Products
    Smiths Medical partners with Parkview Health to enhance patient and clinician safety
    Parkview Health’s integration of the Smiths Medical PharmGuard® Infusion Management System enables smart pump programming and auto documentation to improve safety.
  5. Infusion Products
    Smiths Medical and Bainbridge Health Partner To Offer Webinar On Emerging Trends In Intravenous Medication Safety and Utilization
    Join our webinar - The Insight to Action: How Visibility on Infusion Pump Data Can Promote Better Use of Clinical Decision Support in the Perioperative Environment.
  6. Infusion Products
    ECRI Evaluation of CADD®-Solis V4 Wireless Ambulatory Infusion System

    The report highlights ECRI’s evaluation ratings, test results, and purchasing recommendations for the CADD®-Solis pump.

  7. Pain Management Products
    Launch of Portex® EchoGlo® Peripheral Nerve Block Portfolio

    Smiths Medical, a leading medical device manufacturer, is excited to announce the launch of its EchoGlo® peripheral nerve block portfolio. This addition to the Portex® portfolio of pain management products offers customers a complete solution for regional anesthesia from pump to patient.

  8. Infusion Products
    CADD®-Solis Wireless Communication - Cybersecurity Bulletin

    Smiths Medical is aware of, and currently monitoring, the Cybersecurity and Infrastructure Security Agency (CISA) notification concerning the Cybersecurity Vulnerability, ICSA-20-168-011 (the “Advisory”).

  9. Infusion Products
    Smiths Medical’s Pain Management System with Wireless Communication in Global Markets
    Smiths Medical has released the CADD®-Solis ambulatory infusion pump version 4.2 that sets the foundation for wireless communication globally. 
  10. Infusion Products
    Successful Deployment of Bi-Directional Interoperability at University Health System

    Smiths Medical announced today that University Health System (UHS) in San Antonio, Texas has gone live with the PharmGuard® Infusion Management Software System with Bi-Directional Interoperability with Epic.

  11. Infusion Products
    Worldwide Notification Regarding Potential for Inappropriate Bolus or Loading Dose Delivery in Certain Medfusion® 3500 and 4000 Infusion Pumps
    Due to a software error, if a bolus or loading dose is interrupted and a specific sequence of events occurs, over- or under-delivery of a bolus or loading dose may occur.
  12. Sharps Safety Products
    Smiths Medical partners with U.S. government on COVID-19 vaccine efforts

    The partnership with BARDA and JPEO-CBRND includes a $20 million investment for increased syringe and needle device production to support Operation Warp Speed vaccine program.

PreviousNext